LYSOSOMAL ACID LIPASE DEFICIENCY TREATMENT MARKET ANALYSIS

Lysosomal Acid Lipase Deficiency Treatment Market, by Therapy Type (Liver Transplant and Hematopoietic Stem Cell Transplant), By Drug Type (Statins and Other Dyslipidemia Drugs and Sebelipase Alfa (Kanuma)), By Disease Indication (Wolman Disease and Cholesteryl Ester Storage Disease (CESD)), and By Geography - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Dec 2024
Code : CMI904
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Ltd. In 2015, FDA approved Kanuma, an innovative enzyme replacement therapy (ERT) in the U.S., Europe Union, and Japan, which is providing an opportunity to manufacturers for exploring their business in the untapped market. Major players operating in global Lysosomal Acid Lipase (LAL) Deficiency treatment market include Alexion Pharmaceutical Inc., Merck & Co., Inc., Pfizer, Inc., and AstraZeneca plc. and Teva Pharmaceutical Industries.